CN1636009A - A1 腺苷受体的部分和全促效药 - Google Patents

A1 腺苷受体的部分和全促效药 Download PDF

Info

Publication number
CN1636009A
CN1636009A CNA038041936A CN03804193A CN1636009A CN 1636009 A CN1636009 A CN 1636009A CN A038041936 A CNA038041936 A CN A038041936A CN 03804193 A CN03804193 A CN 03804193A CN 1636009 A CN1636009 A CN 1636009A
Authority
CN
China
Prior art keywords
tetrahydrofuran
compound
optionally substituted
diol
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038041936A
Other languages
English (en)
Chinese (zh)
Inventor
普拉巴·易卜拉欣
埃尔法蒂赫·埃尔扎因
凯文·申克
罗伯特·江
杰夫·扎布沃茨基
李小芬
克里斯托弗·莫里森
陶佩里
肖登明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1636009A publication Critical patent/CN1636009A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA038041936A 2002-02-19 2003-02-19 A1 腺苷受体的部分和全促效药 Pending CN1636009A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35796102P 2002-02-19 2002-02-19
US60/357,961 2002-02-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008102118341A Division CN101392012A (zh) 2002-02-19 2003-02-19 A1腺苷受体的部分和全促效药

Publications (1)

Publication Number Publication Date
CN1636009A true CN1636009A (zh) 2005-07-06

Family

ID=27757687

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038041936A Pending CN1636009A (zh) 2002-02-19 2003-02-19 A1 腺苷受体的部分和全促效药
CNA2008102118341A Pending CN101392012A (zh) 2002-02-19 2003-02-19 A1腺苷受体的部分和全促效药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008102118341A Pending CN101392012A (zh) 2002-02-19 2003-02-19 A1腺苷受体的部分和全促效药

Country Status (15)

Country Link
US (3) US7144871B2 (enExample)
EP (2) EP1476455A1 (enExample)
JP (1) JP2005527502A (enExample)
KR (2) KR20040084929A (enExample)
CN (2) CN1636009A (enExample)
AU (2) AU2003223237C1 (enExample)
CA (1) CA2476683C (enExample)
IL (2) IL163613A0 (enExample)
MX (1) MXPA04008008A (enExample)
NO (1) NO330243B1 (enExample)
NZ (1) NZ534801A (enExample)
PL (1) PL372145A1 (enExample)
RU (1) RU2317994C2 (enExample)
WO (1) WO2003070739A1 (enExample)
ZA (1) ZA200406607B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922413A (zh) * 2015-08-26 2018-04-17 詹森药业有限公司 作为prmt5抑制剂的、新颖6‑6二环芳环取代的核苷类似物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
PL372145A1 (en) * 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
CA2573682A1 (en) * 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
RU2443708C2 (ru) * 2007-05-17 2012-02-27 Си Ви Терапьютикс, Инк. Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций
WO2012012736A2 (en) * 2010-07-23 2012-01-26 The Ohio State University Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
TN2018000310A1 (en) 2016-03-10 2020-01-16 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP7101171B2 (ja) 2016-10-03 2022-07-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体
MX391405B (es) 2016-12-15 2025-03-21 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-mll.
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
ES2971035T3 (es) 2017-02-27 2024-06-03 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificación de pacientes con cáncer que mostrarán respuesta al tratamiento con un inhibidor de prmt5
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US10421734B1 (en) * 2018-08-31 2019-09-24 Sami Labs Limited Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
PH12021553075A1 (en) 2019-06-12 2023-09-11 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
AU2020404305A1 (en) 2019-12-19 2022-08-04 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
PL372145A1 (en) * 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922413A (zh) * 2015-08-26 2018-04-17 詹森药业有限公司 作为prmt5抑制剂的、新颖6‑6二环芳环取代的核苷类似物
CN107922413B (zh) * 2015-08-26 2021-10-01 詹森药业有限公司 作为prmt5抑制剂的、新颖6-6二环芳环取代的核苷类似物

Also Published As

Publication number Publication date
KR101032005B1 (ko) 2011-05-02
US7144871B2 (en) 2006-12-05
MXPA04008008A (es) 2005-03-23
PL372145A1 (en) 2005-07-11
RU2317994C2 (ru) 2008-02-27
US20030232783A1 (en) 2003-12-18
EP2412716A1 (en) 2012-02-01
IL163613A (en) 2010-12-30
ZA200406607B (en) 2006-05-31
JP2005527502A (ja) 2005-09-15
AU2008249143B2 (en) 2011-08-25
AU2008249143A1 (en) 2008-12-11
NZ534801A (en) 2006-04-28
US20090325896A1 (en) 2009-12-31
AU2003223237C1 (en) 2009-03-26
IL163613A0 (en) 2005-12-18
NO330243B1 (no) 2011-03-14
CA2476683C (en) 2011-11-01
KR20100046058A (ko) 2010-05-04
AU2003223237A1 (en) 2003-09-09
CN101392012A (zh) 2009-03-25
EP1476455A1 (en) 2004-11-17
CA2476683A1 (en) 2003-08-28
RU2004125492A (ru) 2006-01-27
US7696181B2 (en) 2010-04-13
US20060287275A1 (en) 2006-12-21
WO2003070739A1 (en) 2003-08-28
NO20043907L (no) 2004-09-17
KR20040084929A (ko) 2004-10-06
AU2003223237B2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
CN1636009A (zh) A1 腺苷受体的部分和全促效药
CN1244589C (zh) 腺苷a3受体激动剂
CN1152041C (zh) C－吡唑a2a受体激动剂
CN1166678C (zh) 嘌呤衍生物
CN1249051C (zh) 毒蕈碱性激动剂
CN100349913C (zh) 2′－氟代核苷
CN1086704C (zh) 具有抗高血压、保护心脏、抗局部缺血和抗脂解性质的化合物
CN1020107C (zh) 抗病毒化合物的制备方法
CN1432020A (zh) 嘌呤衍生物
CN1400975A (zh) 嘌呤衍生物
CN1265665A (zh) 苯并咪唑衍生物
CN101068825A (zh) 具有a2a激动剂活性的具有修饰的5＇－核糖基团的2－丙炔基腺苷类似物
CN1268140A (zh) 单环l－核苷、类似物及其应用
CN1617726A (zh) 用于治疗病毒感染的n4－酰基胞嘧啶核苷
CN1378550A (zh) 部分或完全a1激动剂－n6杂环5′硫代腺苷衍生物
CN1612889A (zh) 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
HK1044952B (zh) N-吡唑a2a受体激动剂
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
CN1478085A (zh) 用于治疗冠状动脉疾病或动脉粥样硬化的abca-1提高化合物
CN1856496A (zh) 抑制hiv复制的嘌呤衍生物
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1871244A (zh) 作为腺苷受体配体的噻唑并吡啶衍生物
CN102014915A (zh) 作为a1腺苷受体的部分和完全激动剂的腺苷衍生物
CN101056875A (zh) 被取代的苯基氨基噻唑类化合物以及其应用
CN1518450A (zh) 腺苷类似物用于制备治疗胰岛素抵抗综合征和糖尿病药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication